Myocarditis Related to COVID-19 and SARS-CoV-2 Vaccination

The coronavirus disease of 2019 (COVID-19) has been a cause of significant morbidity and mortality worldwide. Among the short- and long-term consequences of COVID-19, myocarditis is a disease to be taken into consideration. Myocarditis, in general, is related to a poor prognosis. However, the epidemiology and prognosis of myocarditis related to COVID-19 are currently unknown. While vaccination against COVID-19 is of great benefit at a public health level, the risk of myocarditis should be considered in the context of the global benefits of vaccination. In this narrative review, we will summarize the etiopathogenic bases, the epidemiology, the clinical manifestations, the course, diagnosis, prognosis, and the treatment of myocarditis related to SARS-CoV-2, as well as myocarditis secondary to mRNA vaccines.

[1]  Michael John Smith,et al.  Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. , 2022, JAMA.

[2]  Xianqiang Yu.  Potential of Heparin in the Treatment of COVID-19–Associated Myocarditis , 2022, Pediatric emergency care.

[3]  L. S. Schmidt,et al.  Population-based Incidence of Myopericarditis After COVID-19 Vaccination in Danish Adolescents , 2021, The Pediatric infectious disease journal.

[4]  J. Cooke,et al.  Acute and Chronic Cardiovascular Manifestations of COVID-19: Role for Endotheliopathy , 2021, Methodist DeBakey cardiovascular journal.

[5]  R. Wade,et al.  The binding of heparin to spike glycoprotein inhibits SARS-CoV-2 infection by three mechanisms , 2021, Journal of Biological Chemistry.

[6]  B. Lawson,et al.  Coronavirus disease 2019 and cardiovascular diseases: collateral damage? , 2021, Current opinion in anaesthesiology.

[7]  M. Jaguszewski,et al.  Myocarditis: A complication of COVID-19 and long-COVID-19 syndrome as a serious threat in modern cardiology , 2021, Cardiology journal.

[8]  F. Shakeel,et al.  Efficacy of the early treatment with tocilizumab-hydroxychloroquine and tocilizumab-remdesivir in severe COVID-19 Patients , 2021, Journal of Infection and Public Health.

[9]  Antonio P. DeRosa,et al.  COVID-19 associated myocarditis: A systematic review , 2021, The American Journal of Emergency Medicine.

[10]  A. Tropsha,et al.  Shedding the Light on Post-Vaccine Myocarditis and Pericarditis in COVID-19 and Non-COVID-19 Vaccine Recipients , 2021, Vaccines.

[11]  A. Gundlapalli,et al.  Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data — United States, March 2020–January 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[12]  Yae-Jean Kim,et al.  Epidemiology and Clinical Features of Myocarditis/Pericarditis before the Introduction of mRNA COVID-19 Vaccine in Korean Children: a Multicenter Study , 2021, Journal of Korean medical science.

[13]  P. Hotez,et al.  Myocarditis With COVID-19 mRNA Vaccines , 2021, Circulation.

[14]  Jeong‐Wook Seo,et al.  Myocarditis-induced Sudden Death after BNT162b2 mRNA COVID-19 Vaccination in Korea: Case Report Focusing on Histopathological Findings , 2021, Journal of Korean medical science.

[15]  E. A. Kogan,et al.  Subacute and chronic post-covid myoendocarditis: clinical presentation, role of coronavirus persistence and autoimmune mechanisms. , 2021, Kardiologiia.

[16]  K. Batra,et al.  In-Depth Evaluation of a Case of Presumed Myocarditis After the Second Dose of COVID-19 mRNA Vaccine , 2021, Circulation.

[17]  L. Cooper,et al.  Myocarditis after BNT162b2 and mRNA-1273 Vaccination. , 2021, Circulation.

[18]  Tiffani J. Johnson,et al.  Myopericarditis in a previously healthy adolescent male following COVID‐19 vaccination: A case report , 2021, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[19]  E. Michos,et al.  COVID and Cardiovascular Disease: What We Know in 2021 , 2021, Current Atherosclerosis Reports.

[20]  C. Giannattasio,et al.  Temporal relation between second dose BNT162b2 mRNA Covid-19 vaccine and cardiac involvement in a patient with previous SARS-COV-2 infection , 2021, IJC Heart & Vasculature.

[21]  G. Finocchiaro,et al.  COVID-19 and myocarditis: a systematic review and overview of current challenges , 2021, Heart Failure Reviews.

[22]  Javier García,et al.  [Acute myocarditis after administration of the BNT162b2 vaccine against COVID-19]. , 2021, Revista espanola de cardiologia.

[23]  Javier Bautista García,et al.  Miocarditis aguda tras administración de vacuna BNT162b2 contra la COVID-19 , 2021, Revista Española de Cardiología.

[24]  M. Oster,et al.  Factors linked to severe outcomes in multisystem inflammatory syndrome in children (MIS-C) in the USA: a retrospective surveillance study , 2021, The Lancet Child & Adolescent Health.

[25]  R. Virmani,et al.  Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis , 2021, Journal of the American College of Cardiology.

[26]  R. Heads,et al.  COVID-19 and Toll-Like Receptor 4 (TLR4): SARS-CoV-2 May Bind and Activate TLR4 to Increase ACE2 Expression, Facilitating Entry and Causing Hyperinflammation , 2021, Mediators of inflammation.

[27]  Kai Yin,et al.  Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment , 2021, Acta biochimica et biophysica Sinica.

[28]  Ayesha Farooq,et al.  Multisystem Inflammatory Syndrome in Children and Adolescents (MIS-C) under the Setting of COVID-19: A Review of Clinical Presentation, Workup and Management , 2021, Infectious diseases.

[29]  Umair Khalid,et al.  COVID-19 myocarditis and long-term heart failure sequelae. , 2020, Current opinion in cardiology.

[30]  Andrew J. Layman,et al.  COVID-19–Associated Nonocclusive Fibrin Microthrombi in the Heart , 2020, Circulation.

[31]  E. Nagel,et al.  COVID-19 myocarditis and prospective heart failure burden , 2020, Expert review of cardiovascular therapy.

[32]  M. Halushka,et al.  Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations , 2020, Cardiovascular Pathology.

[33]  K. Sawalha,et al.  Systematic Review of COVID-19 Related Myocarditis: Insights on Management and Outcome , 2020, Cardiovascular Revascularization Medicine.

[34]  B. V. Van Tassell,et al.  Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective , 2020, Cardiovascular Drugs and Therapy.

[35]  G. Dangas,et al.  Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019 , 2020, JAMA network open.

[36]  L. Cooper,et al.  Recognizing COVID-19–related myocarditis: The possible pathophysiology and proposed guideline for diagnosis and management , 2020, Heart Rhythm.

[37]  P. Bhargava,et al.  Cardiac Tamponade Secondary to COVID-19 , 2020, JACC: Case Reports.

[38]  Dong Liu,et al.  Tocilizumab treatment in COVID‐19: A single center experience , 2020, Journal of medical virology.

[39]  Giuseppe Citerio,et al.  Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19) , 2020, Intensive Care Medicine.

[40]  Fenglian Ma,et al.  Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin , 2020, European heart journal.

[41]  X. Shuai,et al.  Intravenous Immunoglobulin Therapy for Acute Myocarditis in Children and Adults. , 2019, International heart journal.

[42]  M. Sheppard,et al.  Guidelines for autopsy investigation of sudden cardiac death: 2017 update from the Association for European Cardiovascular Pathology , 2017, Virchows Archiv.